Monahan Joseph 4
4 · Aclaris Therapeutics, Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Monahan Joseph
Chief Scientific Officer
Transactions
- Tax Payment
Common Stock
2025-03-01$1.99/sh−27,258$54,243→ 265,662 total - Exercise/Conversion
Common Stock
2025-03-01+50,000→ 281,995 total - Exercise/Conversion
Common Stock
2025-03-01+10,925→ 292,920 total - Exercise/Conversion
Restricted Stock Units
2025-03-01−50,000→ 0 total→ Common Stock (50,000 underlying) - Exercise/Conversion
Restricted Stock Units
2025-03-01−10,925→ 10,925 total→ Common Stock (10,925 underlying)
Holdings
- 193(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
- [F3]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
- [F4]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.